ArticleCancer treatment reviews2020
Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities.
Article in Cancer treatment reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of coronavirus disease 2019 pandemic on good clinical practice trials in oncology.Exploration of targeted anti-tumor therapy · 2023Pooled it
- TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.Cancer medicine · 2024Article
- Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs.Cancer prevention research (Philadelphia, Pa.) · 2022Article
- When the doorbell rings in COVID-19 times: Numerical insights into some possible scenarios.Physics of fluids (Woodbury, N.Y. : 1994) · 2021Article
- Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420).JCO global oncology · 2021Article
- Cancer Research in the Time of COVID-19: A Colombian Narrative.Frontiers in public health · 2021Article
- Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic.Frontiers in medicine · 2020Review
- Gender Disparities in Concerns of Cancer Research Participation During COVID-19 Climate.Cancer control : journal of the Moffitt Cancer CenterArticle
- Gender Differences in Concerns About Participating in Cancer Research During the COVID-19 Pandemic.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic affected many activities in the healthcare system including oncology drug development. Clinical trial recruitment was temporary halted in many centres to reduce patients and healthcare workers' potential exposure to the virus. Conversely, to continue offering treatments for patients already on effective therapies, multiple actions were timely put in place, resulting in simplification of trial-related procedures for patients and clinicians' best interest, reduction of the operational burden and effective communication. Here, we suggest maintaining effective measures for future trial simplification and to expedite drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.